BrightFocus Foundation is a presentation partner for Turning Point, an award-winning documentary capturing the drama and dedication of scientists and clinical trial volunteers who are working to make Alzheimer’s a distant memory.
Working with Gates Ventures and public and private sector leaders, BrightFocus has screened the film nationally and internationally over 100 times in the past year for community audiences, health care and scientific groups, and policymakers.
Turning Point is an excellent documentary that gives us an inside look at the doctors, scientists, and patients who are working to uncover the mysteries of Alzheimer’s disease through clinical trials…
Everybody should see this film.
- Bill Gates
Learn about Brain Health & Dementia Prevention
Learn more about what choices you can make that may decrease your risk of developing dementia.Learn More
Donate to ResearchSupport Us Now
Take Action Against Alzheimer's
1 in 2 Americans over the age of 85 develop Alzheimer's.
Although it can be difficult to diagnose Alzheimer’s disease, in an estimated 90 percent of cases, physicians can correctly diagnose the condition based on a:
- Recent history of mental and behavioral symptoms
- Physical exam and laboratory tests
- Neuropsychological test, if needed, to identify specific problems in mental function and behavior
About Us: Funding Breakthrough Science
BrightFocus Foundation is a premier source of private research funding to defeat Alzheimer's, macular degeneration, and glaucoma. We are currently managing a global portfolio of nearly 200 research projects, a $40 million investment in the bold, innovative science that will find the cures for diseases of mind and sight. We share the latest research findings and best practices to empower families impacted by these diseases.
Recent BrightFocus-sponsored findings in Alzheimer's disease have indicated that
- Alzheimer’s disease may spread by ‘jumping’ from one brain region to another.
- Cell energy dysfunction is present early in Alzheimer's, before memory loss.
- Specialized antibodies have about ten times the ability of a regular antibody to neutralize the toxic clustering of the misfolded Alzheimer's beta-amyloid protein.
With further research, each of these discoveries may contribute to the development of new treatments and preventions.
To learn more, please explore these articles and resources:
- What's new in the Alzheimer's treatment pipeline?
- What's the difference between dementia and Alzheimer's disease?
- Decreasing your risk of Alzheimer's disease
- Alzheimer's Disease Toolkit
The film was funded through a grant by Eli Lilly and Company to Volunteers of America. PCH Films retained full editorial control of all content and messaging in the film.
This content was last updated on: November 6, 2019